-
1
-
-
0030796665
-
The cost-effectiveness of clozapine. A UK clinic-based study
-
Aitchison KJ, Kerwin RW. The cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry. 1997 ; 171: 125-130
-
(1997)
Br J Psychiatry
, vol.171
, pp. 125-130
-
-
Aitchison, K.J.1
Kerwin, R.W.2
-
2
-
-
33644821818
-
Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?
-
Annemans L. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?. Pharmacoeconomics. 2005 ; 23 (suppl 1). 1-2
-
(2005)
Pharmacoeconomics
, vol.23
, Issue.SUPPL. 1
, pp. 1-2
-
-
Annemans, L.1
-
3
-
-
27644545591
-
Head-to-head comparison of the costs of atypical antipsychotics: A systematic review
-
DOI 10.2165/00023210-200519110-00004
-
Barbui C, Lintas C, Percudani M. Head-to-head comparison of the costs of atypical antipsychotics: a systematic review. CNS Drugs. 2005 ; 19: 935-950 (Pubitemid 41571993)
-
(2005)
CNS Drugs
, vol.19
, Issue.11
, pp. 935-950
-
-
Barbui, C.1
Lintas, C.2
Percudani, M.3
-
4
-
-
67349119802
-
UK cost consequence analysis of aripiprazole in schizophrenia: Diabetes and coronary heart risk projections (STAR study)
-
Barnett AH, Millar HL, Loze JY, l'Italien GJ, Baardewijk M, Knapp M. UK cost consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci. 2009 ;:
-
(2009)
Eur Arch Psychiatry Clin Neurosci
-
-
Barnett, A.H.1
Millar, H.L.2
Loze, J.Y.3
L'Italien, G.J.4
Baardewijk, M.5
Knapp, M.6
-
7
-
-
0033830383
-
Causes of the excess mortality of schizophrenia
-
Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000 ; 177: 212-217
-
(2000)
Br J Psychiatry
, vol.177
, pp. 212-217
-
-
Brown, S.1
Inskip, H.2
Barraclough, B.3
-
8
-
-
42149127173
-
-
Canterbury: Personal Social Services Research Unit, The University of Kent ;
-
Curtis L, Netten A Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, The University of Kent ; 2006 :
-
(2006)
Unit Costs of Health and Social Care
-
-
Curtis, L.1
Netten, A.2
-
9
-
-
0027985147
-
Economics and schizophrenia: The real cost
-
Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. 1994 ; 25 (suppl). 18-21 (Pubitemid 24331669)
-
(1994)
British Journal of Psychiatry
, vol.165
, Issue.NOV. SUPPL. 25
, pp. 18-21
-
-
Davies, L.M.1
Drummond, M.F.2
-
10
-
-
34447131002
-
Cost-effectiveness of first- v. second-generation antipsychotic drugs: Results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
-
DOI 10.1192/bjp.bp.106.028654
-
Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007 ; 191: 14-22 (Pubitemid 47035176)
-
(2007)
British Journal of Psychiatry
, vol.191
, Issue.JULY
, pp. 14-22
-
-
Davies, L.M.1
Lewis, S.2
Jones, P.B.3
Barnes, T.R.E.4
Gaughran, F.5
Hayhurst, K.6
Markwick, A.7
Lloyd, H.8
-
11
-
-
0038653525
-
A meta-analysis of the efficacy of second-generation antipsychotics
-
DOI 10.1001/archpsyc.60.6.553
-
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 ; 60: 553-564 (Pubitemid 36682312)
-
(2003)
Archives of General Psychiatry
, vol.60
, Issue.6
, pp. 553-564
-
-
Davis, J.M.1
Chen, N.2
Glick, I.D.3
-
12
-
-
0030056579
-
Guidelines for authors and peer reviewers of economic submissions to the BMJ
-
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996 ; 313: 275-283 (Pubitemid 26254740)
-
(1996)
British Medical Journal
, vol.313
, Issue.7052
, pp. 275-283
-
-
Drummond, M.F.1
Jefferson, T.O.2
-
13
-
-
0034145539
-
The new drugs (chlorpromazine and reserpine): Administrative aspects, 1956
-
Duval AM, Goldman D. The new drugs (chlorpromazine and reserpine): administrative aspects, 1956. Psychiatr Serv. 2000 ; 51: 327-331
-
(2000)
Psychiatr Serv
, vol.51
, pp. 327-331
-
-
Duval, A.M.1
Goldman, D.2
-
14
-
-
33750062845
-
Incidence of schizophrenia and other psychoses in ethnic minority groups: Results from the MRC AESOP Study
-
DOI 10.1017/S0033291706008774, PII S0033291706008774
-
Fearon P, Kirkbride J, Morgan C, et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: rsults from the MRC AESOP Study. Psychol Med. 2006 ; 36: 1541-1550 (Pubitemid 44575800)
-
(2006)
Psychological Medicine
, vol.36
, Issue.11
, pp. 1541-1550
-
-
Fearon, P.1
Kirkbride, J.B.2
Morgan, C.3
Dazzan, P.4
Morgan, K.5
Lloyd, T.6
Hutchinson, G.7
Tarrant, J.8
Lun Alan Fung, W.9
Holloway, J.10
Mallett, R.11
Harrison, G.12
Leff, J.13
Jones, P.B.14
Murray, R.M.15
Muga, F.16
Mietunen, J.17
Ashby, M.18
Hayhurst, H.19
Craig, T.20
McCabe, J.21
Samele, C.22
Gwenzi, E.23
Sharpley, M.24
Vearnals, S.25
Hutchinson, G.26
Burnett, R.27
Kelly, J.28
Orr, K.29
Salvo, J.30
Greenwood, K.31
Raune, D.32
Lambri, M.33
Jones, S.34
Auer, S.35
Rohebak, P.36
McIntosh, L.37
Doody, G.38
Window, S.39
Williams, P.40
Bagalkote, H.41
Dow, B.42
Boot, D.43
Farrant, A.44
Jones, S.45
Simpson, J.46
Moanette, R.47
Sirip Suranim, P.Z.48
Ruddell, M.49
Brewin, J.50
Medley, I.51
more..
-
15
-
-
0033064214
-
Cost of schizophrenia to UK society: An incidence-based cost-of-illness model for the first 5 years following diagnosis
-
DOI 10.2165/00019053-199915060-00007
-
Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics. 1999 ; 15: 597-610 (Pubitemid 29256520)
-
(1999)
PharmacoEconomics
, vol.15
, Issue.6
, pp. 597-610
-
-
Guest, J.F.1
Cookson, R.F.2
-
16
-
-
33644829405
-
Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectivness models
-
Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectivness models. Pharmacoeconomics. 2005 ; 23 (suppl 1). 3-16
-
(2005)
Pharmacoeconomics
, vol.23
, Issue.SUPPL. 1
, pp. 3-16
-
-
Haycox, A.1
-
17
-
-
0021154534
-
The quality of life scale: An instrument for rating the schizophrenic deficit syndrome
-
Heinrichs DN, Hanton TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984 ; 10: 388-398
-
(1984)
Schizophr Bull
, vol.10
, pp. 388-398
-
-
Heinrichs, D.N.1
Hanton, T.E.2
Carpenter, W.T.3
-
18
-
-
33749321169
-
Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia
-
Jones PB, Barnes T.R.E, Davies L, et al. Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry. 2006 ; 63: 1079-1087
-
(2006)
Arch Gen Psychiatry
, vol.63
, pp. 1079-1087
-
-
Jones, P.B.1
Tre, B.2
Davies, L.3
-
19
-
-
33847623330
-
Predicting costs of mental health care: A critical literature review
-
DOI 10.1017/S0033291706009676, PII S0033291706009676
-
Jones J, Amaddeo F, Barbui C, Tansella M. Predicting costs of mental health care: a critical literature review. Psychol Med. 2007 ; 37: 467-477 (Pubitemid 46359596)
-
(2007)
Psychological Medicine
, vol.37
, Issue.4
, pp. 467-477
-
-
Jones, J.1
Amaddeo, F.2
Barbui, C.3
Tansella, M.4
-
20
-
-
34447117847
-
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study
-
DOI 10.1016/j.eurpsy.2007.03.002, PII S0924933807012886
-
Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community treated schizophrenic patients Schzophrenia Trial of Aripiprazole: (STAR Study). Eur Psychiatry. 2007 ; 22: 433-443 (Pubitemid 47600616)
-
(2007)
European Psychiatry
, vol.22
, Issue.7
, pp. 433-443
-
-
Kerwin, R.1
Millet, B.2
Herman, E.3
Banki, C.M.4
Lublin, H.5
Pans, M.6
Hanssens, L.7
L'Italien, G.8
McQuade, R.D.9
Beuzen, J.-N.10
-
21
-
-
0030719980
-
Costs of schizophrenia
-
Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997 ; 171: 509-518 (Pubitemid 27527318)
-
(1997)
British Journal of Psychiatry
, vol.171
, Issue.DEC.
, pp. 509-518
-
-
Knapp, M.1
-
22
-
-
33745328794
-
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
-
Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess (Rockv). 2006 ; 10: 1-165
-
(2006)
Health Technol Assess (Rockv)
, vol.10
, pp. 1-165
-
-
Lewis, S.W.1
Davies, L.2
Jones, P.B.3
-
23
-
-
25144456112
-
For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigator: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
Lieberman JA, Stroup TS, McEvoy JP, et al. For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigator: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223
-
(2005)
N Engl J Med
, vol.353
, pp. 1209-1223
-
-
Lieberman, J.A.1
Stroup, T.S.2
McEvoy, J.P.3
-
24
-
-
57749189344
-
How far have we got in pharmacoeconomics for psychiatry and where are we going?
-
McCrone P, Aitchison KJ, Taylor D. How far have we got in pharmacoeconomics for psychiatry and where are we going?. Clin Neuropsychiatry, J Treatment Evaluation. 2008 ; 5 (4). 173-174
-
(2008)
Clin Neuropsychiatry, J Treatment Evaluation
, vol.5
, Issue.4
, pp. 173-174
-
-
McCrone, P.1
Aitchison, K.J.2
Taylor, D.3
-
25
-
-
45349099523
-
Change in sexual dysfunction with aripiprazole: A switching or add-on study
-
DOI 10.1177/0269881107082901
-
Mir A, Shivakumar K, Williamson RJ, McAllister VDM, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008 ; 22: 244-253 (Pubitemid 351847447)
-
(2008)
Journal of Psychopharmacology
, vol.22
, Issue.3
, pp. 244-253
-
-
Mir, A.1
Shivakumar, K.2
Williamson, R.J.3
McAllister, V.4
O'Keane, V.5
Aitchison, K.J.6
-
26
-
-
33750069721
-
Raising the bar for treatment expectations in schizophrenia: Achieving remission as a routine goal of antipsychotic pharmacotherapy
-
DOI 10.1177/1359786806071221
-
Nasrallah HA, Dursun SM. Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy. J Psychopharmacol. 2006 ; 20 (suppl 6). 3-5 (Pubitemid 44583373)
-
(2006)
Journal of Psychopharmacology
, vol.20
, Issue.6 SUPPL.
, pp. 3-5
-
-
Nasrallah, H.A.1
Dursun, S.M.2
-
27
-
-
33750073822
-
Improving patient outcomes in schizophrenia: Achieving remission
-
DOI 10.1177/1359786806071248
-
Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol. 2006 ; 20 (suppl 6). 57-61 (Pubitemid 44583377)
-
(2006)
Journal of Psychopharmacology
, vol.20
, Issue.6 SUPPL.
, pp. 57-61
-
-
Nasrallah, H.A.1
Lasser, R.2
-
28
-
-
14744290059
-
Defining and measuring clinical effectiveness in the treatment of schizophrenia
-
DOI 10.1176/appi.ps.56.3.273
-
Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005 ; 56: 273-282 (Pubitemid 40333559)
-
(2005)
Psychiatric Services
, vol.56
, Issue.3
, pp. 273-282
-
-
Nasrallah, H.A.1
Targum, S.D.2
Tandon, R.3
McCombs, J.S.4
Ross, R.5
-
30
-
-
57749207241
-
Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of schizophrenia
-
Ohlsen RI, Taylor D, Tandon K, Aitchison KJ. Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of schizophrenia. Clin Neuropsychiatry, J Treatment Evaluation. 2008 ; 5 (4). 184-194
-
(2008)
Clin Neuropsychiatry, J Treatment Evaluation
, vol.5
, Issue.4
, pp. 184-194
-
-
Ohlsen, R.I.1
Taylor, D.2
Tandon, K.3
Aitchison, K.J.4
-
31
-
-
29744458402
-
Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms
-
DOI 10.1007/s00406-005-0622-6
-
Riedel M, Müller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005 ; 255: 432-437 (Pubitemid 43029832)
-
(2005)
European Archives of Psychiatry and Clinical Neuroscience
, vol.255
, Issue.6
, pp. 432-437
-
-
Riedel, M.1
Muller, N.2
Strassnig, M.3
Spellmann, I.4
Engel, R.R.5
Musil, R.6
Dehning, S.7
Douhet, A.8
Schwarz, M.J.9
Moller, H.-J.10
-
32
-
-
1642580680
-
Selection of Atypical Antipsychotics for the Management of Schizophrenia
-
DOI 10.1345/aph.1C461
-
Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother. 2004 ; 38: 313-319 (Pubitemid 38112247)
-
(2004)
Annals of Pharmacotherapy
, vol.38
, Issue.2
, pp. 313-319
-
-
Sprague, D.A.1
Loewen, P.S.2
Raymond, C.B.3
-
33
-
-
57749192240
-
The cost effectiveness of atypical versus typical antipsychotics
-
Tandon K, Aitchison KJ. The cost effectiveness of atypical versus typical antipsychotics. Psychiatry. 2002 ; 1: 66-69
-
(2002)
Psychiatry
, vol.1
, pp. 66-69
-
-
Tandon, K.1
Aitchison, K.J.2
-
34
-
-
0037214276
-
Efficacy of newer generation antipsychotics in the treatment of schizophrenia
-
DOI 10.1016/S0306-4530(02)00110-5
-
Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003 ; 28 (suppl 1). 9-26 (Pubitemid 36015659)
-
(2003)
Psychoneuroendocrinology
, vol.28
, Issue.SUPPL. 1
, pp. 9-26
-
-
Tandon, R.1
Jibson, M.D.2
-
35
-
-
33747481325
-
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)
-
DOI 10.1016/j.schres.2005.12.857, PII S0920996406000144
-
Tandon R, Marcus RN, Stock EG, et al. A prospective, multicentre, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness trial with aripiprazole (BETA). Schizophr Res. 2006 ; 84: 77-89 (Pubitemid 44255718)
-
(2006)
Schizophrenia Research
, vol.84
, Issue.1
, pp. 77-89
-
-
Tandon, R.1
Marcus, R.N.2
Stock, E.G.3
Riera, L.C.4
Kostic, D.5
Pans, M.6
McQuade, R.D.7
Nyilas, M.8
Iwamoto, T.9
Crandall, D.T.10
|